Feb 09, 2018 6:45am EST Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration
Dec 07, 2017 8:30am EST Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402
Nov 21, 2017 8:30am EST Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors
Nov 08, 2017 4:30pm EST Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update
Nov 02, 2017 8:00am EDT Pieris Pharmaceuticals to Host Third Quarter 2017 Investor Call and Corporate Update on November 9, 2017
Oct 12, 2017 8:00am EDT Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Oct 02, 2017 8:00am EDT Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343
